Sugammadex

Generic Name: Sugammadex

Brand Names: Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal

Drug Type: Small Molecule

Chemical Formula: C_₇₂H_₁₁₂O_₄₈S_₈

CAS Number: 343306-71-8

Unique Ingredient Identifier: 361LPM2T56

Background: Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...

Indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.

Associated Conditions: Neuromuscular blockade caused by vecuronium bromide

Associated Therapies: -

Clinical Trials

Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex

Phase 4

Completed

Conditions: Underdosing of Other General Anesthetics

Interventions: Drug: sugammadex

First Posted Date: 2013-10-18

Last Posted Date: 2014-08-15

Lead Sponsor: MSD Korea Ltd.

Target Recruit Count: 60

Registration Number: NCT01965067

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Hanyang University Hospital, Seoul, Korea, Republic of

Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade

Phase 4

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: rocuronium
Drug: sugammadex
Drug: placebo

First Posted Date: 2013-09-02

Last Posted Date: 2015-03-30

Lead Sponsor: Herlev Hospital

Target Recruit Count: 14

Registration Number: NCT01933425

Locations: 🇩🇰
Department of minimal invasive gynecology Aleris-Hamlet Private Hospital, Copenhagen, Søborg, Denmark

The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients

Not Applicable

Completed

Conditions: Anesthesia Recovery Period, Neuromuscular Blockade

Interventions: Drug: Sugammadex

First Posted Date: 2013-07-01

Last Posted Date: 2014-02-04

Lead Sponsor: Severance Hospital

Target Recruit Count: 44

Registration Number: NCT01890057

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of

Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade

Phase 3

Conditions: Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Placebo

First Posted Date: 2013-05-16

Last Posted Date: 2013-05-17

Lead Sponsor: St. Antonius Hospital

Target Recruit Count: 25

Registration Number: NCT01855217

Locations: 🇳🇱
Sint Antonius Ziekenhuis, Nieuwegein, Netherlands

Reversal of Neuromuscular Blockade in Thoracic Surgical Patients

Completed

Conditions: Residual Neuromuscular Blockade

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2013-04-23

Last Posted Date: 2020-02-13

Lead Sponsor: NorthShore University HealthSystem

Target Recruit Count: 200

Registration Number: NCT01837498

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial

Phase 3

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2013-03-13

Last Posted Date: 2014-03-06

Lead Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

Target Recruit Count: 100

Registration Number: NCT01809886

Locations: 🇪🇸
Mª Dolores Cárceles Barón, El Palmar, Murcia, Spain

A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)

Phase 4

Completed

Conditions: Gallbladder Disease

Interventions: Drug: Rocuronium
Other: Insufflation
Drug: Sugammadex

First Posted Date: 2012-11-20

Last Posted Date: 2018-10-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 127

Registration Number: NCT01728584

Locations: 🇩🇪
Merck Sharp & Dohme GmbH, Haar, Germany
🇮🇹
MSD Italia S.r.l., Rome, Italy

Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients

Phase 2

Conditions: Morbid Obesity
Neuromuscular Blockade

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2012-06-27

Last Posted Date: 2012-06-27

Lead Sponsor: University of Patras

Target Recruit Count: 120

Registration Number: NCT01629394

Locations: 🇬🇷
University of Patras, Department of Anesthesiology and Critical Care Medicine, Patras, Achaia, Greece

Recovery After Sugammadex(Propofol vs Sevoflurane)

Phase 4

Completed

Conditions: Anesthesia

Interventions: Drug: Sugammadex

First Posted Date: 2012-04-18

Last Posted Date: 2017-05-22

Lead Sponsor: Hopital Foch

Target Recruit Count: 71

Registration Number: NCT01579851

Locations: 🇫🇷
Hopital Foch, Suresnes, Ile de France, France

Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal

Phase 4

Completed

Conditions: Underdosing of Skeletal Muscle Relaxants for Laparotomy
Reversal of Skeletal Muscle Relaxant

Interventions: Drug: Neostigmine, atropine
Drug: Sugammadex

First Posted Date: 2012-02-27

Last Posted Date: 2015-08-07

Lead Sponsor: Hospital Sultanah Aminah Johor Bahru

Target Recruit Count: 49

Registration Number: NCT01539044

Locations: 🇲🇾
Hospital Sulatanah Aminah, Johor Bahru, Johor, Malaysia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy